Ken Mulvany

Ivan Griffin

Brent Gutekunst

Michael Brennan

BenevolentAI S.A.

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Machine Translation utilizes computational biology, novel Machine Learning & AI, bioinformatic simulations, and a unique data set to determine which drug candidates will most likely succeed in clinical studies.

Machine Translation

NyquistAI provides AI-powered solutions to transform clinical and regulatory data and documentation into actionable insights for Life Sciences professionals.

NyquistAI

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Metric
Company Name	BenevolentAI S.A.	BridgeBio Pharma	Machine Translation	NyquistAI
Symbol	BAI
MSH ID	COM:BENEVOLENT	COM:BRIDGEBIOPHARMA	COM:MACHTRANSPRO	COM:NYQUISTAI
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector		Healthcare & Health Services	Healthcare & Health Services	Technology
Industry		Biotechnology	Biotechnology	Healthcare & Health Services
Country		US	US	US
Stage		Post-IPO Equity
Employee Count
Website		bridgebiopharma.com	machtranspro.com	nyquistai.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	12.91K	23.81K	162.88K
Web Traffic Growth	0.76	0.19	-0.34
Valuation
Raised Capital		250M

Metric
Revenue	9.34M
Revenue (LTM)
Revenue (NTM)
Gross Profit	9.34M
EBITDA	-89.02M
Operating Income	-98.85M
Net Income	-80.68M
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-10.58
EBITDA Margin	-9.53
Net Profit Margin	-8.64
Return on Equity	-0.51
Return on Assets	-0.51
Return on Capital Employed	-0.79

BAI

COM:BENEVOLENT

BenevolentAI

Last Close

0.73

25/11 08:06

Volume Today

2.39K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.43
P/B Ratio	0.46
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.42
EV Multiple	-0.82

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.06

Metric
Operating Cash Flow	-72.79M
Free Cash Flow	-74.20M
Cash Flow to Debt	-10.46
Operating Cash Flow/Sales	-7.28
Free Cash Flow Yield	-1.03

Metric
Cash & Equivalents	46.48M
Accounts Receivable
Inventory
Goodwill	29.92M
Debt to Capitalization	0.05
Debt to Assets	0.04
Current Ratio	5.93
Quick Ratio	3.65

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	3.20
R&D to Revenue	6.16
SG&A to Revenue	3.03